Halozyme Therapeutics stock

HALO · NASDAQ · USD

Compare Halozyme Therapeutics
$95.97Change from previous close: −0.55%Absolute change: −$0.53

Close · November 17, 2026

Price history

+35.81% over the period

1 year: from $70.56 (November 17, 2025) to $95.83 (November 17, 2026), +35.81%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$95.83
October 30, 2026$130.91
September 30, 2026$110.40
August 31, 2026$106.49
July 31, 2026$82.54
June 30, 2026$78.27
May 29, 2026$66.54
April 30, 2026$63.66
March 31, 2026$64.63
February 27, 2026$69.53
January 30, 2026$71.71
December 31, 2025$67.30
November 28, 2025$71.40
November 17, 2025$70.56

At a glance

  • The company

    Biopharmaceutical company developing proprietary enzymes and devices that enable enhanced delivery of injectable biologics and other therapeutic molecules

  • Latest results

    Quarter to September 30, 2026 · EPS $2.39 (estimate $2.28)

TickerLandia's take on Halozyme Therapeutics

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$61.23
52-wk high$129.69

−26.00% from the 52-week high

Analysts · 9 analysts

Average target$108.78+13.35% vs. price

Buy 7 · Hold 2 · Sell 0 · Buy

TickerLandia Fingerprint: Halozyme Therapeutics

Compared with similar companies: very high profitability.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Halozyme Therapeutics is pricier than in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Halozyme Therapeutics's P/E today is 37.4, above the median of its last 7 fiscal years (26.3; between 13.9 and 46.9 from 2017 to 2025). Halozyme Therapeutics's P/E (trailing 12 months): 38.3, in line with the median of a group of 7 similar companies (38.3).

P/E compared with its history

Compared with 7 similar companies

Halozyme Therapeutics's metrics compared with similar companies
MetricHalozyme TherapeuticsPosition in the groupBand
P/E (trailing 12 months)38.3Middle
Forward P/E9.19Middle
Operating margin56.8%High
ROE173.7%High
Debt/equity15.2High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Halozyme Therapeutics. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$481M

Latest quarter · Q2 2026

Net income

$229.91M

Latest quarter · Q2 2026

Quarterly net margin

47.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$14.67B
P/E
38.3
EPS
$3.97
Volume
717.82K
Daily trading
€248.38M

How Halozyme Therapeutics is changing

All results
  • Revenue grew 39.2% a year on average over the last 5 years

  • Operating margin fell from 40.5% to 33.6%

  • Profits turn into cash: free cash flow equal to 143% of net income

Returns

Halozyme Therapeutics returns

$1,000 invested in Halozyme Therapeutics 5 years ago, on November 17, 2021, would be worth $2,603 today: +160.27% in total, +21.09% per year. This is the price return only: dividends are excluded.

PeriodHalozyme TherapeuticsS&P 500$1,000 becomes
1 month−21.77%−3.17%$782
6 months+42.98%+0.11%$1,430
Year to date+42.39%+8.34%$1,424
1 year+35.81%+11.15%$1,358
3 years+139.99%+64.30%$2,400
5 years+160.27%+58.18%$2,603
10 years+638.29%+239.10%$7,383

Over the last 6 months it has done better than 82% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Halozyme Therapeutics: technical analysis

Halozyme Therapeutics shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 26.8% below its all-time closing high ($131.18, October 29, 2026).

Trend
No clear trend
RSI (14 sessions)
23
Below 30: a strong fall in a short time
vs 200-session average
+12.04%

Active signals

  • Close below the low of the previous 55 sessions.

    since November 16, 2026

  • RSI below 30: the stock has fallen a lot in a short time.

    since November 6, 2026

Support and resistance

Price areas where Halozyme Therapeutics has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$111.15+15.82%2 touches, last on September 4, 2026
  2. Resistance$104.49+8.87%2 touches, last on September 16, 2026
  3. Last price$95.97
  4. Support$82.24−14.31%2 touches, last on July 7, 2026
  5. Support$74.40−22.47%4 touches, last on July 15, 2026
  6. Support$70.75−26.28%4 touches, last on June 9, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.62
Volatility (60 sessions, annualised)
46.1%
Largest fall in the last year
−26.84%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Halozyme Therapeutics: seasonality

Average monthly price change over 23 years

−0.5%Jan+2.3%Feb+3.8%Mar−0.7%Apr+0.7%May+5.0%Jun+3.6%Jul+0.7%Aug+2.1%Sep−1.8%Oct+6.5%Nov+11.0%Dec

Over the last 23 years, the strongest month for Halozyme Therapeutics has been December: +11.04% on average, positive in 12 years out of 22. The weakest has been October: −1.81% on average, positive in 11 years out of 23. November, the current month, has been positive in 14 years out of 22 (+6.55% on average).

Show chart data
MonthAverageMedianPositive years
January−0.52%+1.22%11 of 22
February+2.28%+2.80%13 of 22
March+3.84%+0.37%11 of 22
April−0.71%+0.19%13 of 23
May+0.65%+0.93%13 of 23
June+4.96%+8.64%14 of 23
July+3.60%+1.81%15 of 23
August+0.66%+1.60%12 of 23
September+2.13%−1.85%9 of 23
October−1.81%−1.23%11 of 23
November+6.55%+5.81%14 of 22
December+11.04%+0.43%12 of 22

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Halozyme Therapeutics and its competitors

Halozyme is known for Hylenex and XYOSTED, and for its patented recombinant human hyaluronidase enzyme, rHuPH20, which lets injectable biologics be delivered under the skin. Its partners market subcutaneous versions of well-known cancer, autoimmune and immunodeficiency therapies, including Herceptin Hylecta, Phesgo, Tecentriq SC, Ocrevus SC, HYQVIA and DARZALEX, and the company also works with argenx, Pfizer, AbbVie and Eli Lilly. Its licensing collaborations and its own proprietary enzymes and devices reach markets in the United States, Switzerland, Belgium, Japan and beyond.

Headquarters
San Diego, United States
Employees
423
Founded
1998
Chief executive
Helen Torley
Halozyme Therapeutics and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Halozyme TherapeuticsHALO$14.67B56.8%38.3+42.98%
BridgeBio PharmaBBIO$15.25B-37.3%—+16.13%
Jazz PharmaceuticalsJAZZ$15.5B27.4%71.5+5.22%
ExelixisEXEL$16.37B40.2%20.1+36.64%
Ascendis PharmaASND$18.06B30.9%18.1+12.76%
Bio-TechneTECH$11.43B21.7%66.8+67.74%

Same industry or related industries, similar size. Compare Halozyme Therapeutics with its competitors · Full profile